Inositol monophosphatase 1
Inositol monophosphatase 1 is an enzyme that in humans is encoded by the IMPA1 gene.[5][6]
Interacting partners
IMPA1 has been shown to interact with Bergmann glial S100B[7] and calbindin.[8][9]
Chemical inhibitors
L-690,330 is a competitive inhibitor of IMPase activity with very good activity in vitro however with limited bioavailability in vivo.[10] Due to its increased specificity compared to Lithium, L-690,330 has been used extensively in characterizing the results of IMPase inhibition in various cell culture models. L-690,488, a prodrug or L-690,330, has also been developed which has greater cell permeability. Treatment of cortical slices with L-690,488 resulted in accumulation of inositol demonstrating the activity of this inhibitor in tissue.[11]
Inhibition of IMPA1 activity can have pleiotropic effects on cellular function, including altering phosphoinositide signalling,[12] autophagy, apoptosis,[13] and other effects.
Bipolar disorder
Initially it was noticed that several drugs useful in treatment of biopolar disorder such as lithium, carbamazepine and valproic acid had a common mechanism of action on enzymes in the phosphatidylinositol signalling pathway[14] and the inositol depletion hypothesis for the pathophysiology of biopolar disorder was suggested. Intensive research has so far not confirmed this hypothesis, partly because lithium can also act on a number of other enzymes in this pathway, complicating results from in vitro studies.
References
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000133731 - Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000027531 - Ensembl, May 2017
- ↑ "Human PubMed Reference:".
- ↑ "Mouse PubMed Reference:".
- ↑ McAllister G, Whiting P, Hammond EA, Knowles MR, Atack JR, Bailey FJ, Maigetter R, Ragan CI (Aug 1992). "cDNA cloning of human and rat brain myo-inositol monophosphatase. Expression and characterization of the human recombinant enzyme". Biochem J. 284 (3): 749–54. PMC 1132602
. PMID 1377913. - ↑ "Entrez Gene: IMPA1 inositol(myo)-1(or 4)-monophosphatase 1".
- ↑ Vig PJ, Shao Q, Subramony SH, Lopez ME, Safaya E (September 2009). "Bergmann glial S100B activates myo-inositol monophosphatase 1 and Co-localizes to purkinje cell vacuoles in SCA1 transgenic mice". Cerebellum. 8 (3): 231–44. PMC 3351107 . PMID 19593677. doi:10.1007/s12311-009-0125-5.
- ↑ Schmidt H, Schwaller B, Eilers J (April 2005). "Calbindin D28k targets myo-inositol monophosphatase in spines and dendrites of cerebellar Purkinje neurons". Proc. Natl. Acad. Sci. U.S.A. 102 (16): 5850–5. PMC 556286 . PMID 15809430. doi:10.1073/pnas.0407855102.
- ↑ Berggard T, Szczepankiewicz O, Thulin E, Linse S (November 2002). "Myo-inositol monophosphatase is an activated target of calbindin D28k". J. Biol. Chem. 277 (44): 41954–9. PMID 12176979. doi:10.1074/jbc.M203492200.
- ↑ Atack JR, Cook SM, Watt AP, Fletcher SR, Ragan CI (February 1993). "In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330". J. Neurochem. 60 (2): 652–8. PMID 8380439. doi:10.1111/j.1471-4159.1993.tb03197.x.
- ↑ Atack JR, Prior AM, Fletcher SR, Quirk K, McKernan R, Ragan CI (July 1994). "Effects of L-690,488, a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690,330, on phosphatidylinositol cycle markers". J. Pharmacol. Exp. Ther. 270 (1): 70–6. PMID 8035344.
- ↑ King JS, Teo R, Ryves J, Reddy JV, Peters O, Orabi B, Hoeller O, Williams RS, Harwood AJ (2009). "The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells". Dis Model Mech. 2 (5-6): 306–12. PMC 2675811 . PMID 19383941. doi:10.1242/dmm.001271.
- ↑ Sarkar S, Rubinsztein DC (2006). "Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations". Autophagy. 2 (2): 132–4. PMID 16874097. doi:10.4161/auto.2387.
- ↑ Williams RS, Cheng L, Mudge AW, Harwood AJ (May 2002). "A common mechanism of action for three mood-stabilizing drugs". Nature. 417 (6886): 292–5. PMID 12015604. doi:10.1038/417292a.
Further reading
- Bone R, Springer JP, Atack JR (1992). "Structure of inositol monophosphatase, the putative target of lithium therapy". Proc. Natl. Acad. Sci. U.S.A. 89 (21): 10031–10035. PMC 50271 . PMID 1332026. doi:10.1073/pnas.89.21.10031.
- Hallcher LM, Sherman WR (1981). "The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain". J. Biol. Chem. 255 (22): 10896–901. PMID 6253491.
- Bone R, Frank L, Springer JP, et al. (1994). "Structural analysis of inositol monophosphatase complexes with substrates". Biochemistry. 33 (32): 9460–9467. PMID 8068620. doi:10.1021/bi00198a011.
- Bone R, Frank L, Springer JP, Atack JR (1994). "Structural studies of metal binding by inositol monophosphatase: evidence for two-metal ion catalysis". Biochemistry. 33 (32): 9468–9476. PMID 8068621. doi:10.1021/bi00198a012.
- Ganzhorn AJ, Lepage P, Pelton PD, et al. (1996). "The contribution of lysine-36 to catalysis by human myo-inositol monophosphatase". Biochemistry. 35 (33): 10957–10966. PMID 8718889. doi:10.1021/bi9603837.
- Parthasarathy L, Parthasarathy R, Vadnal R (1997). "Molecular characterization of coding and untranslated regions of rat cortex lithium-sensitive myo-inositol monophosphatase cDNA". Gene. 191 (1): 81–87. PMID 9210592. doi:10.1016/S0378-1119(97)00045-0.
- Sjøholt G, Molven A, Løvlie R, et al. (1997). "Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA)". Genomics. 45 (1): 113–122. PMID 9339367. doi:10.1006/geno.1997.4862.
- Nemanov L, Ebstein RP, Belmaker RH, et al. (1999). "Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels". The International Journal of Neuropsychopharmacology. 2 (1): 25–29. PMID 11281967. doi:10.1017/S1461145799001315.
- Bahn JH, Kim AY, Jang SH, et al. (2002). "Production of monoclonal antibodies and immunohistochemical studies of brain myo-inositol monophosphate phosphatase". Mol. Cells. 13 (1): 21–7. PMID 11911470.
- Atack JR, Schapiro MB (2002). "Inositol monophosphatase activity in normal, Down syndrome and dementia of the Alzheimer type CSF". Neurobiol. Aging. 23 (3): 389–396. PMID 11959401. doi:10.1016/S0197-4580(01)00335-9.
- Berggard T, Szczepankiewicz O, Thulin E, Linse S (2003). "Myo-inositol monophosphatase is an activated target of calbindin D28k". J. Biol. Chem. 277 (44): 41954–41959. PMID 12176979. doi:10.1074/jbc.M203492200.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–16903. PMC 139241 . PMID 12477932. doi:10.1073/pnas.242603899.
- Sjøholt G, Ebstein RP, Lie RT, et al. (2005). "Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder". Mol. Psychiatry. 9 (6): 621–629. PMID 14699425. doi:10.1038/sj.mp.4001460.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–2127. PMC 528928 . PMID 15489334. doi:10.1101/gr.2596504.
- Rual JF, Venkatesan K, Hao T, et al. (2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature. 437 (7062): 1173–1178. PMID 16189514. doi:10.1038/nature04209.
- Ohnishi T, Ohba H, Seo KC, et al. (2007). "Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1". J. Biol. Chem. 282 (1): 637–646. PMID 17068342. doi:10.1074/jbc.M604474200.
PDB gallery | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.